While our study emphasizes the importance of rigorous testing of HDTs for TB in multiple translational models prior to implementation in human trials, we also show that immunomodulation of the IL-1 pathway did not exacerbate TB disease. The gene discussed is IL1B; the disease is tuberculosis.